Licofelone derivatives and methods of use
Patent Number: WO2017015013
 
Executive Summary:
  • Invention Type: Therapeutic
  • Patent Status: Application
  • Patent Link: https://www.google.com/patents/WO2017015013
  • Research Institute: University of Oklahoma
  • Disease Focus: Colorectal cancer
  • Basis of Invention: Chemical compound derived from licofelone
  • How it works: COX-2 plays a key role in colorectal cancer progression and metastasis. COX-2 has therefore been an attractive target for selective inhibitors, and the resulting decrease in PGE2 has been shown to have protective effects in animal models and clinical research. However, in addition to decreased PGE2, inhibition of COX-2 also results in decreased PGI2 and increased leukotrienes, associated with a higher risk of thrombosis and cardiovascular events. Licofelone is a competitive inhibitor of 5-LOX, COX-1 and COX-3 inhibitor, decreasing the production of both PGs and leukotrienes, thereby reducing inflammation and pain with low gastrotoxicity
  • Lead Challenge Inventor: Chinthalapally V. Rao
  • Inventors: Chinthalapally V. Rao, Naveena B. Janakirem, Hariprasas Gali, Altaf Mohammed, Gopal Pathuri
  • Development Stage: Pre-clinical
  • Novelty:
    • Novel molecular target, novel inhibitor
  • Clinical Applications:
    • Administration of compound to suppress inflammation and reduce pain and inflammation with colorectal cancer

General Description:
The invention describes derivatives of licofelone for treatment of chronic inflammatory diseases and colorectal cancer. The agents are highly sensitive and selective. Furthermore, this compound results in reduced gastrotoxicity and the associated inflammation and pain compared to current drugs on the market.
 
Strengths:
  • Highly specific
  • Highly sensitive
  • Reduced toxicity

Patent Status:
  • Priority date: 2015-07-17
  • Application date: 2017-01-26
 
Inventor Bio: Chinthalapally V. Rao
https://www.oumedicine.com/docs/ad-medicine-workfiles/c-v-rao-phd-.pdf?sfvrsn=0